AT-Patch (ATP-C130/ATP-C70) vs syngo MBF

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

AT-Patch (ATP-C130/ATP-C70)

by ATsens Co.

syngo MBF

by Siemens Healthineers

AI Verdict

Tool A specializes in continuous cardiac electrical activity monitoring for arrhythmia detection via a wearable ECG device. In contrast, Tool B provides AI-enhanced quantitative analysis of myocardial blood flow using PET imaging for perfusion assessment. While both are cardiology AI tools, they address distinct diagnostic needs related to heart rhythm versus myocardial perfusion.

Choose AT-Patch (ATP-C130/ATP-C70) if…

Choose AT-Patch if you require continuous, long-term ambulatory ECG monitoring for up to 14 days to detect intermittent arrhythmias or evaluate treatment effectiveness. Its lightweight, shower-proof design and integrated AI analysis make it ideal for patient comfort and efficient arrhythmia detection in a real-world setting.

View AT-Patch (ATP-C130/ATP-C70) →

Choose syngo MBF if…

Choose syngo MBF if your clinical practice requires advanced quantitative analysis of myocardial blood flow (MBF) and myocardial flow reserve (MFR) using PET imaging. This AI-enhanced software is best suited for detailed cardiac diagnostics, particularly for assessing myocardial perfusion and viability, and can be integrated into existing syngo.via workflows for comprehensive cardiac assessment.

View syngo MBF →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	AT-Patch (ATP-C130/ATP-C70)	syngo MBF
Pricing	N/a	Contact vendor
Deployment	Wearable device for patients; analysis software deployed on-premise at medical institutions.	On-premise (dedicated hardware), Virtualized environments (VMware, Hyper-V)
BAA Available	Unknown	Yes AI-estimated
FDA Status	Cleared AI-estimated	Yes AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

AT-Patch (ATP-C130/ATP-C70)

AT-Patch's design prioritizes patient usability with a compact, lightweight, shower-proof wearable that requires no charging during monitoring, and an intuitive smartphone app for live viewing and symptom recording. This focus on patient comfort and ease of adherence for continuous monitoring gives it an edge in overall usability for its primary user.

Clinical Value

Tie

Both tools are FDA-cleared and deliver significant, distinct clinical value in cardiology. AT-Patch excels in long-term arrhythmia detection, while syngo MBF provides critical quantitative myocardial blood flow analysis for PET imaging, addressing different but equally important diagnostic needs.

Pricing & Value

Tie

Neither AT-Patch nor syngo MBF provides publicly available pricing information. Both require direct engagement with their respective vendors for pricing details, making a direct comparison of their pricing transparency or value assessment impossible.

Enterprise Readiness

syngo MBF

syngo MBF explicitly states it is HIPAA compliant and has a Business Associate Agreement (BAA), and supports deployment in virtualized environments, which are strong indicators of enterprise readiness. AT-Patch's HIPAA compliance is only stated as 'likely' and BAA is 'not explicitly mentioned', placing Tool B ahead in this dimension.

Innovation

Tie

Both tools demonstrate significant innovation by integrating AI into their core functionalities. AT-Patch combines hardware innovation (wearable design) with AI for patient-facing arrhythmia detection, while syngo MBF applies AI to complex quantitative PET image analysis and workflow acceleration within a specialized diagnostic platform.

Support & Docs

syngo MBF

Siemens Healthineers, the company behind syngo MBF, offers a comprehensive 'Support & Documentation' portal, including a 'Document Library' for technical documents, manuals, and an 'IT Care Plan' with 24/7 remote support and educational resources. While AT-Patch provides user manuals and an app, Siemens' established enterprise-level support infrastructure is more robust.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	AT-Patch (ATP-C130/ATP-C70)	syngo MBF
Name	AT-Patch (ATP-C130/ATP-C70)	syngo MBF
Company	ATsens Co.	Siemens Medical Solutions USA, Inc.
Description	FDA-cleared wearable ECG monitor offering up to 14 days of continuous cardiac monitoring with high accuracy, a shower-proof design, and integrated AI-powered analysis software for enhanced arrhythmia detection.	FDA-cleared, AI-enhanced software for quantitative myocardial blood flow (MBF) analysis using PET imaging. Integrated within the syngo.via platform, it provides advanced tools for cardiac diagnostics and therapy response assessment.
Categories	Cardiology AI, Wearables & Remote Monitoring (RPM)	Cardiology AI, Radiology & Imaging AI
Specialties	Cardiology, Family Medicine, Internal Medicine	Cardiology, Nuclear Medicine, Radiology
Key Features	Up to 14 days of continuous ECG monitoring (ATP-C130), High-performance sensor chip for accurate ECG signal acquisition, Short-length electrode to minimize motion artifact noise, Shower-proof design (IP57 for ATP-C130, IP44 for ATP-C70), No charging or electrode replacement required during monitoring, Compact and lightweight (13g) for patient comfort, AT-Note smartphone app for live ECG viewing and symptom recording, AT-Report software with AI/machine learning algorithms for ECG analysis	Quantitative Myocardial Blood Flow (MBF) and Myocardial Flow Reserve (MFR) calculation, Supports dynamic Rubidium-PET and Ammonia-PET images, Automatic and manual myocardium orientation and segmentation tools, Normals database comparison workflow, Motion compensation and residual activity correction, Multi-modality image reading (via syngo.via platform), AI-powered Automatic Landmarking and Parsing of Human Anatomy (ALPHA) for workflow acceleration (via syngo.via platform), Fast 3D results and advanced visualization

Videos

Demos, reviews, and walkthroughs featuring AT-Patch (ATP-C130/ATP-C70) and syngo MBF.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What is the primary diagnostic focus of AT-Patch compared to syngo MBF?

AT-Patch is an FDA-cleared wearable ECG monitor designed for up to 14 days of continuous cardiac monitoring, primarily for enhanced arrhythmia detection. In contrast, syngo MBF is an FDA-cleared, AI-enhanced software for quantitative myocardial blood flow (MBF) analysis using PET imaging, focusing on cardiac diagnostics and therapy response assessment.

How do the data acquisition methods differ between the two tools?

AT-Patch acquires data directly from the patient via a compact and lightweight wearable ECG device. syngo MBF analyzes existing dynamic Rubidium-PET and Ammonia-PET images, integrating within the syngo.via platform.

Which medical specialties are these tools primarily designed for?

AT-Patch is intended for Cardiology, Family Medicine, and Internal Medicine. syngo MBF is designed for Cardiology, Nuclear Medicine, and Radiology specialties.

What specific AI capabilities does each tool offer?

AT-Patch features integrated AI/machine learning algorithms for ECG analysis and enhanced arrhythmia detection. syngo MBF utilizes AI for quantitative myocardial blood flow analysis and AI-powered Automatic Landmarking and Parsing of Human Anatomy (ALPHA) for workflow acceleration within the syngo.via platform.

Does AT-Patch provide quantitative myocardial blood flow analysis, or does syngo MBF offer continuous cardiac monitoring?

No, AT-Patch provides continuous ECG monitoring for arrhythmia detection, not myocardial blood flow analysis. Conversely, syngo MBF performs quantitative myocardial blood flow analysis using PET imaging and does not offer continuous cardiac monitoring.